Effects Of The Direct Renin Inhibitor Aliskiren On Oxidative Stress In Isolated Rat Heart

1. Angeli F, Reboldi G, Mazzotta G, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf. 2012;7(1):76-85.10.2174/15748861280049277122663961Search in Google Scholar

2. Dzau V. The cardiovascular continuum and renin-angiotensinaldosterone system blockade. J Hypertens-Suppl. 2005; 23: S9-17.10.1097/01.hjh.0000165623.72310.ddSearch in Google Scholar

3. Pagliaro P, Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther. 2005; 19: 77-87.10.1007/s10557-005-6900-8708760115883759Search in Google Scholar

4. Angeli F, Reboldi G, Poltronieri C et al. Efficacy and safety profile of aliskiren: practical implications for clinicians. Curr Drug Saf. 2014; 9(2): 106-17.10.2174/138945011566614021111304024517108Search in Google Scholar

5. Sen S, Sabırlı S, Ozyiğit T, Uresin Y. Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. TherAdv Chronic Dis. 2013; 4(5): 232-41.10.1177/2040622313495288375218323997927Search in Google Scholar

6. Yoshitomi Y, Kawanishi K, Yamaguchi A, et al. Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension. Int Heart J. 2013; 54(2): 88-92.10.1536/ihj.54.8823676368Search in Google Scholar

7. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs. 2007; 67(12): 1767-92.10.2165/00003495-200767120-0000817683174Search in Google Scholar

8. Zaporowska-Stachowiak I, Hoffmann K, Bryl W, Minczykowski A. Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension. Arch Med Sci. 2014; 10(4): 830-6.10.5114/aoms.2013.34723417575825276171Search in Google Scholar

9. Maibaum J, Feldman DL. Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Pat. 2003; 13: 589–603.10.1517/13543776.13.5.589Search in Google Scholar

10. Fogari R, Zoppi A. New class of agents for treatment of hypertension: focus on direct renin inhibition. Vasc Health Risk Manag. 2010; 6: 869–82.10.2147/VHRM.S4189295245520957132Search in Google Scholar

11. Lizakowski S, Tylicki L, Rutkowski B. Direct renin inhibition – a promising strategy for renal protection? Med SciMonit. 2013; 19: 451–7.Search in Google Scholar

12. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007; 370: 221–9.10.1016/S0140-6736(07)61124-6Search in Google Scholar

13. McMurray JJV, Pitt B, Latini R et al. Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008; 1: 17.10.1161/CIRCHEARTFAILURE.107.740704Search in Google Scholar

14. Ben-Menachem E, Kyllerman M, Marklund S. Superoxide dismutase and gluthatione peroxidase function in progressive myoclonus epilepsies. Epilepsy Res. 2000; 40: 33-9.10.1016/S0920-1211(00)00096-6Search in Google Scholar

15. Naranjan SD, Temsah MR, Netticadan T. Role of oxidative stress in cardiovascular diseases. Journal of hypertension. 2000; 18.6: 655-73.10.1097/00004872-200018060-00002Search in Google Scholar

16. Matavelli LC, Siragy HM. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. J Cardiovasc Pharmacol. 2013; 61(1): 17-22.10.1097/FJC.0b013e318274d2efSearch in Google Scholar

17. Wen Zhang, Yi Han, GuoliangMeng, et al. Direct Renin Inhibition With Aliskiren Protects Against Myocardial Ischemia/Reperfusion Injury by Activating Nitric Oxide Synthase Signaling in Spontaneously Hypertensive Rats. J Am Heart Assoc. 2014; 3(1): e000606.10.1161/JAHA.113.000606Search in Google Scholar

18. Green, LC, Wagner DA, Glogowski J, Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R. Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids. Anal. Biochem. 1982; 126: 131–8.Search in Google Scholar

19. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal, Biochem. 1979; 95: 351–8.10.1016/0003-2697(79)90738-3Search in Google Scholar

20. Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J. Immunol. Methods. 1980; 38: 161–70.Search in Google Scholar

21. Auclair C, Voisin E. Nitroblue tetrazolium reduction. In: Handbook of methods for oxygen radical research, (Ed R.A. Greenvvald). 1985; 123–32. CRC Press, Boca Raton.Search in Google Scholar

22. Frohlich ED. State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension. 1999; 34: 782–9.10.1161/01.HYP.34.4.78210523361Search in Google Scholar

23. Weng LQ, Zhang WB, Ye Y et al. Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice. Acta Pharmacol Sin. 2014; 35(8): 1005-14.10.1038/aps.2014.45412571424998254Search in Google Scholar

24. Santuzzi CH, Tiradentes RV, Mengal V et al. Combined aliskiren and L-arginine treatment has antihypertensive effects and prevents vascular endothelial dysfunction in a model of renovascular hypertension. Braz J Med Biol Res. 2015; 48(1): 65-76.10.1590/1414-431x20144191428849525493385Search in Google Scholar

25. Savvatis K, Westermann D, Schultheiss HP, Tschope C. First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination. Integr Blood Press Control. 2010; 3: 163–70.Search in Google Scholar

26. Duprez DA, Davis P, Botha J. The Ageless Study: The effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients =65 years of age with systolic hypertension. Circulation.2008; 118: 886–7.10.1161/circ.118.suppl_18.S_886-cSearch in Google Scholar

27. Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003; 42: 1137–43.10.1161/01.HYP.0000101688.17370.8714597641Search in Google Scholar

28. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111: 1012-8.10.1161/01.CIR.0000156466.02908.ED15723979Search in Google Scholar

29. Schmieder RE, Philipp T, Guerediaga J et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009; 119: 417–25.10.1161/CIRCULATIONAHA.107.75074519139391Search in Google Scholar

30. Lu H, Rateri DL, Feldman DL et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008; 118(3): 984-93.10.1172/JCI32970224261818274671Search in Google Scholar

31. Renke M, Lizakowski S, Tylicki L, et al. Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study. Adv Med Sci. 2014; 59(2): 256-60.10.1016/j.advms.2014.03.00325105662Search in Google Scholar

32. Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008; 52(3): 563-72.10.1161/HYPERTENSIONAHA.108.11112018645051Search in Google Scholar

33. Yamamoto E, Kataoka K, Dong YF et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension. 2009; 54(3): 633-8.10.1161/HYPERTENSIONAHA.109.13388419597038Search in Google Scholar

34. Imanishi T, Tsujioka H, Ikejima H et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008; 52(3): 563-72.10.1161/HYPERTENSIONAHA.108.111120Search in Google Scholar

35. Kamal S. Aliskiren Augments the Activities of Anti-Oxidant Enzymes in Liver Homogenates of DOCA Salt-Induced Hypertensive Rats. SciRes. 2014; 2: 92-9.10.4236/aer.2014.22010Search in Google Scholar